← Back to news
Industry

3rd Peptide-Based Therapeutics Summit Opens in Boston as Industry Hits Inflection Point

#conference#peptide summit#Boston#industry#oral peptides#AI drug design#peptide market

The 3rd Peptide-Based Therapeutics Summit returns to Boston this April, arriving at a moment when the peptide drug industry is experiencing what many attendees are calling an inflection point. The conference — the only dedicated platform for peptide drug discovery and development — brings together researchers, pharmaceutical executives, biotech founders, and regulatory experts to assess where the field stands and where it is headed.

An Industry Transformed

The timing could not be more relevant. In the past 12 months alone, the peptide therapeutics landscape has undergone changes that would have seemed implausible just two years ago:

  • Oral peptides have arrived. The FDA approved ICOTYDE (icotrokinra), the first oral peptide targeting IL-23 for psoriasis, and Foundayo (orforglipron), an oral GLP-1 agonist for obesity — proving that peptides no longer require injection.
  • The market is booming. Global peptide therapeutics revenue is projected to hit $54.6 billion in 2026, up from $49.2 billion in 2025, driven by the explosive growth of GLP-1 receptor agonists like semaglutide and tirzepatide.
  • AI is reshaping discovery. Among peptide-drug conjugates entering clinical trials since 2022, 78% now use AI-optimized components, up from less than 15% before 2020. Companies like Daiichi Sankyo (partnering with Meddenovo for AI-designed cyclic peptides) are making computational design standard practice.
  • Regulation is in flux. The FDA is expected to reclassify approximately 14 previously restricted peptides back to Category 1 status, reopening compounding pharmacy access under physician supervision.

Key Themes on the Agenda

The summit's program reflects the three forces reshaping the industry:

Oral delivery platforms are the headline topic. Multiple sessions will examine how cyclic peptides, macrocyclic structures, and small-molecule mimetics are making injectable-only delivery obsolete. Unnatural Products, fresh from a $45M Series B, and Pinnacle Medicines ($89M Series B) are among the presenting companies.

AI and computational design sessions will explore how machine learning is compressing peptide discovery timelines from years to months. Daiichi Sankyo's collaboration with Meddenovo and the growing roster of AI-first peptide startups signal a permanent shift in how the industry designs candidates.

Manufacturing scale-up remains a critical bottleneck. With GLP-1 demand still outstripping supply — Novo Nordisk committed $12 billion to manufacturing expansion — the summit will address how peptide production must evolve to meet a market that could exceed $100 billion by 2030.

Why It Matters Now

For an industry that spent decades as a niche corner of pharmaceutical development, the peptide field has arrived at the center of drug discovery. The convergence of oral delivery breakthroughs, AI-accelerated design, GLP-1 commercial success, and regulatory reclassification has created what one summit organizer called "the most exciting period in peptide science since the discovery of insulin."

The question the summit will try to answer: Can the industry scale its science, manufacturing, and regulatory infrastructure fast enough to meet the demand that is already here?